BIO-TECHNE Corp (NASDAQ:TECH) has earned a consensus recommendation of “Buy” from the eleven research firms that are covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $189.13.
A number of equities research analysts have weighed in on TECH shares. Zacks Investment Research raised shares of BIO-TECHNE from a “hold” rating to a “strong-buy” rating and set a $238.00 target price on the stock in a report on Wednesday, May 8th. ValuEngine lowered shares of BIO-TECHNE from a “buy” rating to a “hold” rating in a report on Tuesday, May 7th. BidaskClub raised shares of BIO-TECHNE from a “hold” rating to a “buy” rating in a report on Wednesday, May 1st. Craig Hallum reissued a “hold” rating and set a $179.00 target price (up from $154.00) on shares of BIO-TECHNE in a report on Tuesday, February 5th. Finally, Argus reissued a “buy” rating on shares of BIO-TECHNE in a report on Monday, March 4th.
In other news, CFO James Hippel sold 35,000 shares of the company’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $203.08, for a total value of $7,107,800.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 3.80% of the company’s stock.
TECH stock traded down $1.71 during trading on Friday, reaching $195.69. 6,921 shares of the company were exchanged, compared to its average volume of 174,953. The stock has a market cap of $7.37 billion, a price-to-earnings ratio of 48.04, a P/E/G ratio of 4.16 and a beta of 1.24. BIO-TECHNE has a twelve month low of $132.75 and a twelve month high of $207.84. The company has a debt-to-equity ratio of 0.44, a current ratio of 4.32 and a quick ratio of 3.36.
BIO-TECHNE (NASDAQ:TECH) last released its quarterly earnings data on Tuesday, April 30th. The biotechnology company reported $1.21 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.94 by $0.27. The business had revenue of $184.86 million during the quarter, compared to analysts’ expectations of $183.92 million. BIO-TECHNE had a net margin of 17.15% and a return on equity of 13.53%. The firm’s quarterly revenue was up 12.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.21 EPS. On average, equities research analysts anticipate that BIO-TECHNE will post 3.9 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 24th. Stockholders of record on Friday, May 10th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date of this dividend is Thursday, May 9th. BIO-TECHNE’s dividend payout ratio is currently 31.45%.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.
Recommended Story: Market Capitalization
Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.